CA2955441C - Conjugues de dextrane pour cibler les macrophages et d'autres cellules exprimant cd296 - Google Patents

Conjugues de dextrane pour cibler les macrophages et d'autres cellules exprimant cd296 Download PDF

Info

Publication number
CA2955441C
CA2955441C CA2955441A CA2955441A CA2955441C CA 2955441 C CA2955441 C CA 2955441C CA 2955441 A CA2955441 A CA 2955441A CA 2955441 A CA2955441 A CA 2955441A CA 2955441 C CA2955441 C CA 2955441C
Authority
CA
Canada
Prior art keywords
compound
cancer
disclosed
independently
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2955441A
Other languages
English (en)
Other versions
CA2955441A1 (fr
Inventor
Larry Schlesinger
Eric BACHELDER
Fred COPE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardinal Health 414 LLC
Ohio State Innovation Foundation
Original Assignee
Cardinal Health 414 LLC
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardinal Health 414 LLC, Ohio State Innovation Foundation filed Critical Cardinal Health 414 LLC
Publication of CA2955441A1 publication Critical patent/CA2955441A1/fr
Application granted granted Critical
Publication of CA2955441C publication Critical patent/CA2955441C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés et des compositions pour cibler les macrophages et autres cellules à expression élevée de CD206.
CA2955441A 2014-07-17 2015-07-17 Conjugues de dextrane pour cibler les macrophages et d'autres cellules exprimant cd296 Active CA2955441C (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462025991P 2014-07-17 2014-07-17
US62/025,991 2014-07-17
US201462027193P 2014-07-21 2014-07-21
US201462027220P 2014-07-21 2014-07-21
US62/027,193 2014-07-21
US62/027,220 2014-07-21
US201462027733P 2014-07-22 2014-07-22
US62/027,733 2014-07-22
PCT/US2015/041019 WO2016011419A1 (fr) 2014-07-17 2015-07-17 Compositions pour le ciblage de macrophages et autres cellules à expression élevée de cd206 et méthodes de traitement et de diagnostic

Publications (2)

Publication Number Publication Date
CA2955441A1 CA2955441A1 (fr) 2016-01-21
CA2955441C true CA2955441C (fr) 2023-03-14

Family

ID=55079110

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2955441A Active CA2955441C (fr) 2014-07-17 2015-07-17 Conjugues de dextrane pour cibler les macrophages et d'autres cellules exprimant cd296

Country Status (3)

Country Link
EP (1) EP3169336A4 (fr)
CA (1) CA2955441C (fr)
WO (1) WO2016011419A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196272A1 (en) 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
JP6722663B2 (ja) * 2014-07-17 2020-07-15 オハイオ ステート イノベーション ファウンデーション マクロファージおよび他のマンノース結合ｃ型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法
US10806803B2 (en) 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
WO2018067751A1 (fr) * 2016-10-04 2018-04-12 Navidea Biopharmaceuticals, Inc. Compositions et méthodes de diagnostic et de traitement de troubles liés aux macrophages au moyen d'un support macromoléculaire à base de glucides
US11007272B1 (en) 2016-10-07 2021-05-18 Navidea Biopharmaceuticals, Inc. Compounds and methods for diagnosis and treatment of viral infections
WO2018068059A1 (fr) 2016-10-07 2018-04-12 Navidea Biopharmaceuticals, Inc. Composés et compositions pour le traitement de la leishmaniose et méthodes de diagnostic et de traitement les utilisant
CN111447955A (zh) * 2017-07-21 2020-07-24 纳维迪亚生物制药有限公司 99mTc-替马诺塞和相关的分子构建体用于鉴定和诊断恶性肿瘤和用于监测治疗性抗肿瘤干预的用途
WO2020046835A1 (fr) * 2018-08-27 2020-03-05 Nantbio, Inc. Compositions de rp182 et procédés
CA3134974A1 (fr) * 2019-03-27 2020-10-01 Navidea Biopharmaceuticals, Inc. Compositions et procedes pour modifier un phenotype de macrophage
EP4021459A4 (fr) * 2019-09-30 2023-09-27 Navidea Biopharmaceuticals, Inc. Compositions et procédés associés pour blocage de localisation hors cible de dextrans mannosylés et d'autres ligands cd206
US11859023B2 (en) 2020-07-08 2024-01-02 Navidea Biopharmaceuticals, Inc. Synthesis of uniformly defined molecular weight mannosylated dextrans and derivatives thereof
US11833170B2 (en) 2022-02-04 2023-12-05 Navidea Biopharmaceuticals, Inc. Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking
US12006339B2 (en) 2022-05-20 2024-06-11 Navidea Biopharmaceuticals, Inc. CD206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1069820A (en) * 1965-12-21 1967-05-24 Akad Wissenschaften Ddr Tuberculostatic compounds
WO2000069473A2 (fr) * 1999-05-14 2000-11-23 The Regents Of The University Of California Support macromoleculaire pour medicament et administration d'un agent diagnostique
WO2012169973A1 (fr) * 2011-06-09 2012-12-13 Agency For Science, Technology And Research Nanoparticule à cœur-écorce
JP6722663B2 (ja) * 2014-07-17 2020-07-15 オハイオ ステート イノベーション ファウンデーション マクロファージおよび他のマンノース結合ｃ型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法

Also Published As

Publication number Publication date
EP3169336A1 (fr) 2017-05-24
EP3169336A4 (fr) 2018-04-04
WO2016011419A1 (fr) 2016-01-21
CA2955441A1 (fr) 2016-01-21

Similar Documents

Publication Publication Date Title
CA2955441C (fr) Conjugues de dextrane pour cibler les macrophages et d'autres cellules exprimant cd296
US20230218783A1 (en) Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
US20220211680A1 (en) Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
US10806803B2 (en) Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
US20190365931A1 (en) Double-labeled probe for molecular imaging and use thereof
US20190022259A1 (en) Use of 99mTc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventions
US12005122B2 (en) Compounds and methods for diagnosis and treatment of viral infections
JP2021504453A (ja) 分子イメージングのための二重標識プローブ及びその使用
JP2021502399A (ja) 分子イメージングのための二重標識プローブ及びその使用
US11542267B2 (en) Cryptate compounds
US20170202969A1 (en) Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
US11497763B1 (en) Compounds and methods for treating and diagnosing RNA virus infections
US20240009314A1 (en) Compositions and methods for targeting tumor-associated macrophages

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200714

EEER Examination request

Effective date: 20200714

EEER Examination request

Effective date: 20200714

EEER Examination request

Effective date: 20200714

EEER Examination request

Effective date: 20200714

EEER Examination request

Effective date: 20200714